A Sanofi SA patent describes imidazopyridine compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors and reported to be useful for the treatment of cancer.
Because selective BET inhibitors present better efficacy and safety than pan-BET inhibitors, current research is focused on the development of BD1- or BD2-selective inhibitors.
The company has developed a method of transplantation of human hematopoietic stem cells that allows their engraftment and differentiation into microglial cells.
Researchers at the University of Ottawa have reported on the use of vanoxerine as a suppressor of CSC tumorigenic activity in preclinical models of colorectal cancer.
Vidac Pharma Holdings plc has released promising results for VDA-1275 in mouse cancer and human cellular organoid models of solid tumors, with VDA-1275 showing efficacy as a monotherapy and synergistic effects in combination with sorafenib and cisplatin.
In a recent study, researchers from Technische Universität Dresden and affiliated organizations evaluated the novel small-molecule inhibitor of the CBP/p300 HAT domain, A-485, as a potential therapeutic candidate for the treatment of hematological cancers and other pathologies related to blood leukocyte compartment.
San Francisco-based Xyphos Biosciences Inc. is pooling technology platforms with Boston’s Kelonia Therapeutics Inc. in a novel immuno-oncology (I-O) drug discovery deal that could fetch more than $800 million. Xyphos and Kelonia will collaborate to develop a maximum of two in vivo CAR T-cell therapy programs, utilizing both Kelonia’s in vivo gene placement system called iGPS and Xyphos’ Accel technology platform.
Shanghai Sinotau Biotech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer.
RSS
